Cereno Scientific releases BioStock interview with CEO Sten R. Sörensen regarding the Q2 Report 2024
Cereno Scientific (Nasdaq First North: CRNO B), a pioneering biotech developing innovative treatments for rare and common cardiovascular disease, today announced that a video interview by BioStock has been released with CEO Sten R. Sörensen, commenting on the recently published Q2 Report for 2024, the closing of patient recruitment to the Phase II trial of CS1 in rare disease Pulmonary Arterial Hypertension (PAH), for which topline results will be shared in Q3, the Expanded Access Program (EAP) with CS1 in PAH and CS014 entering into a first-in-human Phase I trial in healthy volunteers.